Egetis Therapeutics AB

EGTX

SE0003815604

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 03:47:05 18/07/2024 pm IST			5-day change	1st Jan Change
6.305 ^SEK	-9.41%		+25.94%	+13.98%

20/06	Transcript : Egetis Therapeutics AB - Special Call
19/06	Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency	CI

PledPharma AB Proposes Marie Ekström Trägårdh as New Member of the Board of Directors

April 25, 2017 at 11:30 am IST

PledPharma AB announced that at the AGM held on April 25, 2017, Marie Ekström Trägårdh is proposed as a new member of the board of directors.

Latest news about Egetis Therapeutics AB

Transcript : Egetis Therapeutics AB - Special Call	20/06
Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency	19/06	CI
Egetis Receives Promising Innovative Medicine Designation in the UK for Emcitate® for Treatment of MCt8 Deficiency	03/06	CI
Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02	CI
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	22/02	CI
Egetis Therapeutics AB Appoints Laetitia Szaller as General Counsel and Head of Compliance	22/12	CI
Transcript : Egetis Therapeutics AB - Analyst/Investor Day	19/12
Egetis Therapeutics AB Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol in the USA	13/12	CI
Egetis Therapeutics Grants Fujimoto Pharmaceutical Exclusive Rights to Emcitate in Japan; Stock Rises	10/11	MT
Egetis Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Egetis Therapeutics' Marketing Authorization Application for Emcitate Validated in EU	27/23/27	MT
Egetis Therapeutics AB Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency	27/23/27	CI
Egetis Therapeutics AB Secures Combined Financing of Approximately SEK 462 Million	11/23/11	CI
Egetis Therapeutics Raises SEK462 Million Via Private Placement, Debt Financing	11/23/11	MT
Egetis Therapeutics AB announced that it expects to receive SEK 461.821824 million in funding from Frazier Life Sciences Management, LP, Cidro Förvaltning AB,	10/23/10	CI
Egetis Therapeutics Seeks Marketing Authorization for Genetic Disorder Treatment in Europe	09/23/09	MT
Egetis Therapeutics AB Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency	09/23/09	CI
Egetis Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	22/23/22	CI
Egetis Therapeutics AB Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial	24/23/24	CI
Transcript : Egetis Therapeutics AB - Special Call	29/23/29
Egetis Therapeutics AB Announces Site Activation in the Pivotal Retriact Trial for Emcitate	29/23/29	CI
Egetis Terminates Discussions Regarding Potential Acquisition	24/23/24	CI
Egetis Therapeutics Ends Talks for Potential Takeover	24/23/24	MT
Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI

Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Companyâs pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.

Sector

Biotechnology & Medical Research

Calendar

21/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Egetis Therapeutics AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.96 SEK

Average target price

13.3 SEK

Spread / Average Target

+91.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
EGETIS THERAPEUTICS AB	+13.98%	193M
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+22.77%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-14.39%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B

Bio Therapeutic Drugs

Egetis Therapeutics AB

Equities

EGTX

SE0003815604

Biotechnology & Medical Research

PledPharma AB Proposes Marie Ekström Trägårdh as New Member of the Board of Directors

Latest news about Egetis Therapeutics AB

Chart Egetis Therapeutics AB

Company Profile

Income Statement Evolution

Ratings for Egetis Therapeutics AB

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs